Summary of clinical research progression of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer

VernacularTitle:甲磺酸阿帕替尼联合多西他赛二线治疗晚期胃癌的临床研究
Author: Mudan YANG ¹ ; Jun GAO ; Xiaoling LIU ; Wenhui YANG ; Hongxia LU
Author Information

1. 山西省肿瘤医院消化二科，太原　030013
Keywords: Gastric neoplasms; Apatinib; Docetaxel; Second-line treatment
From: Chinese Journal of Oncology 2020;42(7):594-597
CountryChina
Language:Chinese
Abstract: Objective:To investigate the progression-free survival (PFS) and safety of apatinib combined with docetaxel treated patients with advanced gastric cancer after failure of first-line chemotherapy.Methods:From March 2017 to May 2018, 23 patients with advanced gastric cancer who had received a failure of first-line chemotherapy (either fedocetaxel or paclitaxel) were treated with apatinib combined with docetaxel. The short-term efficacy and safety of the patients were observed.Results:The therapeutic effects of 20 patients were evaluated. Among them, 4 cases were partial response (PR), 13 patients were stable disease (SD), 3 patients were progressive disease (PD). The objective remission rate (ORR) was 20.0%, the disease control rate (DCR) was 85.0%, the median PFS (mPFS) was 4.5 months. The main adverse reactions were hypertension, vomiting and weakness.Conclusion:Apatinib combined with docetaxel applied in the second-line treatment of gastric cancer is safe and effective.